our Premium Content: News alerts, weekly reports and conference planners

DRUG:

VAX-NK/HCC

News alerts, weekly reports and conference planners

Company:

Vaxcell-Bio Therap

Drug class:

NK cell stimulant

Related drugs:

‹

cytotoxic lymphocyte-based cancer vaccine (0)

AB-101 (0)

CAR-ITNK cells (0)

CAR-NK-CD19 cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CAR19-CYNK (0)

CB CAR-NK019 (0)

CBT101 (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CHM 2301 (0)

CIML NK (0)

CLDN6-CAR-NK cell therapy (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D CAR-NK cell therapy (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

›

1year

Natural Killer (NK) Cell Therapy in Locally Advanced HCC (clinicaltrials.gov)

P2a, N=20, Recruiting, Vaxcell Bio, Co., Ltd. | Trial completion date: Aug 2022 --> May 2024 | Trial primary completion date: Jan 2022 --> Sep 2023

1 year ago

Trial completion date • Trial primary completion date • Metastases

CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL10 (Interleukin 10)

VAX-NK/HCC